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Summary
To determine the prevalence of early-onset Alzheimer
disease (EOAD) and of autosomal dominant forms of
EOAD (ADEOAD), we performed a population-based
study in the city of Rouen (426,710 residents). EOAD
was defined as onset of disease at age !61 years, and
ADEOAD was defined as the occurrence of at least three
EOAD cases in three generations. Using these stringent
criteria, we calculated that the EOAD and ADEOAD
prevalences per 100,000 persons at risk were 41.2 and
5.3, respectively. We then performed a mutational anal-
ysis of the genes for amyloid precursor protein (APP),
presenilin 1 (PSEN1), and presenilin 2 (PSEN2) in 34
families with ADEOAD ascertained in France. In 19
(56%) of these families, we identified 16 distinct PSEN1
missense mutations, including 4 (Thr147Ile, Trp165Cys,
Leu173Trp, and Ser390Ile) not reported elsewhere.APP
mutations, including a novel mutation located at codon
715, were identified in 5 (15%) of the families. In the
10 remaining ADEOAD families and in 9 additional
autosomal dominant Alzheimer disease families that did
not fulfill the strict criteria for ADEOAD, no PSEN1,
PSEN2, or APP mutation was identified. These results
show that (1) PSEN1 and APP mutations account for
71% of ADEOAD families and (2) nonpenetrance at age
!61 years is probably infrequent for PSEN1 or APP
mutations.
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Introduction
Mutations of the presenilin 1 gene (PSEN1), located on
chromosome 14, and of the amyloid precursor protein
gene (APP), located on chromosome 21, have been iden-
tified in families with autosomal dominant forms of
early-onset Alzheimer disease (ADEOAD; MIM 104311
and MIM 104760). To date, 150 different missense mu-
tations of PSEN1 have been described in ∼100 families
(for a recent review, see Rohan de Silva and Patel 1997;
for additional references, see Aoki et al. 1997; Crook et
al. 1997; Forsell et al. 1997; Fox et al. 1997; Gomez-
Isla et al. 1997; Kwok et al. 1997; Lendon et al. 1997a
and 1997b; Yasuda et al. 1997; Aldudo et al. 1998;
Axelman et al. 1998; Harvey et al. 1998; Poorkaj et al.
1998; Wisniewski et al. 1998). In addition, an in-frame
deletion of exon 9, associated with a missense mutation
at the junction point (Perez-Tur et al. 1995b; Crook et
al. 1998), and a deletion affecting the intron 4 splice-
donor consensus sequence and resulting in a premature
stop codon (Tysoe et al. 1998) have also been reported.
APPmutations are less frequent: seven different missense
mutations located in exons 16 and 17 of APP have been
reported (reviewed in Lendon et al. 1997a) in 23 families
with AD or related phenotypes. Although both intra-
and interpedigree variability in age at onset (AAO) ex-
ists, a close examination of the published data shows
that, except for four PSEN1 mutations (Ala79Val [Cruts
et al. 1998], Ile143Phe [Rossor et al. 1996], His163Tyr
[Axelman et al. 1998], and His163Arg [Poorkaj et al.
1998]), PSEN1 and APP mutations are fully penetrant
at the beginning of the 7th decade of life. The case of
two mutations occurring at codon 143 of PSEN1 is of
particular interest, since a nonconservative change
(Ile143Thr) causes AD with an average AAO of 35 years
(Cruts et al. 1995), whereas a semiconservative change
at the same residue (Ile143Phe) causes AD with an av-
erage AAO of 55 years (Rossor et al. 1996) and has also
been detected in an asymptomatic carrier 68 years of
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age. The Glu to Gly substitution occurring at codon 318
of PSEN1 (Sandbrink et al. 1996) was initially consid-
ered an incompletely penetrant mutation (Forsell et al.
1997) but is probably a noncausative polymorphism
(Mattila et al. 1998; Dermaut et al. 1999).
Mutations of a third gene, PSEN2, located on chro-
mosome 1, have also been identified in some autosomal
dominant AD cases (ADAD; MIM 600759). PSEN2mu-
tations are excessively rare, having been described only
in the Volga-German isolate, where a founder effect ex-
ists, and in one Italian family (reviewed in Lendon et al.
1997a). However, the pattern of AAO associated with
PSEN2 mutations is noteworthy and is reminiscent of
that associated with “atypical” PSEN1 mutations, with
AAO of 45–88 years in Met239Val carriers and 40–75
years in Asn141Ile carriers.
The relative contribution of PSEN1 and APP muta-
tions to ADEOAD is the subject of considerable con-
troversy: Hutton and Hardy (1997) have found that, in
a series of 19 families with ADEOAD, all pedigrees could
be explained by PSEN1 or APP mutations, whereas
Cruts et al. (1998) have reported only two PSEN1 mu-
tations, one each in 2 (18%) of 11 kindreds with
ADEOAD that were sampled.
The purpose of this study was (1) to provide, in a
population-based study, a nonbiased estimate of the
prevalence of ADEOAD, (2) to establish, in a large fam-
ily study, the respective contribution of PSEN1, PSEN2,
and APP mutations in the etiology of these autosomal
dominant forms, and (3) to examine the extent to which
PSEN1, PSEN2, and APP mutations are involved in
other forms of familial aggregations of AD.
Subjects and Methods
Prevalence Study
Since 1991, in the city of Rouen and its suburbs (with
426,710 residents, as of March 1, 1991), all general
practitioners, neurologists, and psychiatrists were asked
to refer to the Department of Neurology of the Univer-
sity Hospital all known patients with dementia, the onset
of which occurred at age !61 years. Patients residing in
nursing homes or in the local psychiatric hospital were
considered eligible for inclusion in the study only if they
had been residents of Rouen prior to their institution-
alization. For each patient, a standardized clinical eval-
uation including neurological examination, computed-
tomography scan imaging, and neuropsychological and
laboratory tests were performed (described in detail in
Campion et al. 1995c). Patients fulfilling the criteria of
the National Institute of Neurological and Communi-
cative Disorders and Stroke-Alzheimer’s Disease and Re-
lated Disorder Association for probable AD (McKhann
et al. 1984) were included in this study. The AAO for
AD was defined as the age at which cognitive impairment
began to have a significant impact on social functioning.
For each patient, detailed information concerning sibs,
parents, grandparents, uncles, and aunts was obtained
from the next of kin and was confirmed by at least a
second informant. Whenever possible, medical records
and hospital charts were consulted. This information
was used to categorize our families: families with
ADEOAD were defined by the occurrence of AD cases
with onset at age !61 years in three generations. Alter-
natively, families with ADAD were defined by the pres-
ence of both early- and late-onset cases in three gener-
ations. Accordingly, patients belonging to these two
types of families were referred to as “ADEOAD” and
“ADAD,” respectively.
Information concerning index patients and their fam-
ilies has been updated regularly during the past 7 years.
When the last follow-up was completed in the second
trimester of 1998, prevalences for EOAD and ADEOAD
were calculated by dividing the number of relevant pa-
tients alive on June 1, 1998, by the appropriate denom-
inators determined on the basis of data from the last
(1991) census.
Mutational Analysis
Mutational analysis was performed both in the fam-
ilies with ADEOAD and ADAD identified during the
prevalence study and in additional families with
ADEOAD and ADAD referred to our laboratory by sev-
eral French hospitals. All but three of these additional
families fulfilled the inclusion criteria described above.
These three families (CAE 10, ROU118, and ALZ25)
were nevertheless considered families with ADEOAD,
for the following reasons: in families CAE 10 and
ROU118, only two subjects (the proband and one par-
ent) were affected, but, in both kindreds, one grand-
parent (related to the affected parent) died at age !40
and could therefore be considered an asymptomatic car-
rier. Thus, within these two families, the pattern ob-
served was related to a censoring effect. In the third
family (ALZ25), the proband and his father had the
disease, and the paternal grandparents were dead and
unaffected by age 75 years. The AAO of the affected
subjects (35 and 37 years in the proband and the parent,
respectively) led us to speculate that the presentation of
this family could be explained either by a de novo mu-
tation or by an exclusion of paternity and to consider
this pedigree as a family with ADEOAD.
We analyzed PSEN1 and APP (exons 16 and 17) in
a total of 43 families (34 ADEOAD and 9 ADAD). When
a mutation was found in the proband, additional ped-
igree members were also genotyped to establish the cos-
egregation between the mutation and the disease. In
some families, however, this analysis was not possible,
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Table 1
No. of EOAD and ADEOAD Cases and Prevalences of EOAD and
ADEOAD, by Sex
SEX
NO. OF PREVALENCE OFa
Individuals
at Riskb
EOAD
Patients
ADEOAD
Patients EOAD ADEOAD
Male 46,068 11 2 23.9 4.3
Female 48,525 28 3 57.7 6.2
Overall 94,593 39 5 41.2 5.3
a Per 100,000 inhabitants.
b Age 41–60 years.
Table 2
Kindreds with ADEOAD with PSEN1 Mutations
FAMILY
NO. OF
AAO
(range
[years])
CODON
CHANGE
AMINO ACID
CHANGE
APOE
GENOTYPEa
Affected
Subjects Generations
SAL 508 3 3 53–58 GTGrCTG Val82Leu e3/e3
ALZ 25 2 2 35–37 TATrCAT Tyr115His e3/e4
ALZ 76 3 3 36–47 TATrCAT Tyr115His e3/e3
ALZ 57 4 3 42–53 GAArGAC Glu120Asp e3/e3
CAE 010 2 2 48–50 ATGrACG Met139Thr e3/e3
ALZ 204 6 3 38–47 ATGrCTG Met146Leu b e3/e3
ALZ 047 4 3 37–46 ACTrATT Thr147Ile b,c e3/e3
SAL 001 4 3 42–47 CATrCGT His163Arg b e3/e3
ROU 118 2 2 24–29 TTGrTGG Leu173Trp c e2/e4
ALZ 064 3 3 37–47 TGGrTGC Trp165Cysc e3/e3
ALZ 043 4 3 45–57 GCCrACC Ala231Thr e3/e3
ALZ 079 5 3 38–45 ATGrACG Met233Thrb e3/e3
SAL 510 5 3 29–39 CTGrCCG Leu235Prob e2/e3
SAL 511 6 3 45–56 CCGrCTG Pro264Leub e3/e4
SAL 506 4 3 46–52 CCGrCTG Pro264Leub e3/e4
SAL 1633 4 3 51–55 CCGrCTG Pro264Leu e3/e3
ALZ 059 3 3 42–50 GAArGGA Glu318Glyd e3/e3
ALZ 107 4 3 39–40 AGTrATT Ser390Ilec e3/e3
FAD RO1e 38 5 39–52 CTGrGTG Leu392Valb e3/e3
ROU 011 14 4 40–60 TGTrTAT Cys410Tyrb e2/e3
NOTE.—Several kindreds with PSEN1 mutation have been reported elsewhere (Campion et al.
1995b).
a Of the index case.
b Cosegregation between the mutation and AD could be demonstrated.
c New mutation not reported elsewhere.
d Noncausative polymorphism (Mattila et al. 1998; Dermaut et al. 1999).
e Family included in the population study.
since no affected relative was still alive. When no mu-
tation was found within PSEN1 or APP, we analyzed
PSEN2.
PSEN1 and PSEN2 sequence analysis was performed
on cDNA obtained by reverse transcription–PCR after
extraction of mRNA from lymphoblastoid cell lines, as
described elsewhere (Campion et al. 1995b). For each
gene, the complete open reading frame was amplified
and submitted to gel electrophoresis, to detect a change
affecting the length of the transcript, and was then com-
pletely sequenced (see Campion et al. 1995b; Sherring-
ton et al. 1996; Dumanchin et al. 1998). Sequence anal-
ysis of exons 16 and 17 of APP was performed on
genomic DNA, as described by Campion et al. (1996).
In families with no APP, PSEN1, or PSEN2 mutation,
we also sequenced exons 7, 8, and 18 of APP, using
primers described by Fidani et al. (1992). All sequence
analyses were performed by use of the PRISM
AmpliTaqFS Ready Reaction Dye Primer sequencing kit
(Applied Biosystems, Perkin Elmer Cetus) and an Ap-
plied Biosystems model 373A or 377 automated se-
quencer. For each subject included in either the popu-
lation study or the mutational analysis, APOE genotype
was determined by PCR digestion, according to the
method of Hixson and Vernier (1990).
Results
On June 1, 1998, 39 patients with EOAD (with AAO
!61 years) were living in the town of Rouen; 15 had
isolated cases, and 24 had familial cases defined by the
presence of at least one secondary case among sibs, par-
ents, grandparents, uncles, or aunts. Of the patients with
familial cases, five were from families with ADEOAD.
Although they were ascertained independently, three of
these patients were in fact members of the same very
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Table 3
APP and PSEN2 Analysis in Kindreds with ADEOAD with No PSEN1 Mutation
FAMILY
NO. OF
AAO
(range
[years]) APPa PSEN2a,b
APOE
GENOTYPEc
Affected
Subjects Generations
ALZ 074 4 3 41–60 Val715Met d,e NA e3/e3
FAD R03 6 3 50–60 Val717Ilee NA e3/e3
FAD R04f 5 3 53–55 Val717Ilee NA e3/e3
JUB 001 9 4 38–51 Val717Ilee NA e3/e3
ALZ 066 4 3 53–60 Val717Ile NA e3/e3
ALZ 009 5 3 50–57 WTe WT e3/e4
ALZ 013 10 4 45–56 WT WT e3/e3
ALZ 028 4 3 45–48 WT WT e3/e4
ALZ 036 3 3 52–60 WT WT e3/e4
ALZ 060 3 3 37–58 WT WT e3/e3
ALZ 061 3 3 40–59 WT WT e3/e3
ALZ 063 3 3 45–51 WT WT e3/e4
ALZ 383f 3 3 51–60 WT WT e3/e4
TOU 035 4 3 50–60 WT WT e3/e3
NOTE.—Several kindreds with APP mutation have been reported elsewhere (Campion et al.
1996).
a WT = wild type.
b NA = not analyzed.
c Of the index case.
d New mutation not reported elsewhere.
e Cosegregation between the mutation and AD could be demonstrated.
f Family included in the population study.
Table 4
Families with ADAD Screened for APP, PSEN1, or
PSEN2 Mutations
Familya
No. of
Affected
Subjects
AAO
(range [years])
APOE
Genotypeb
ROU 047c 3 60–65 e3/e3
ALZ 053 6 59–79 e3/e3
ALZ 049 6 60–65 e3/e3
ALZ 062 4 47–66 e3/e3
ALZ 091 4 60–74 e3/e3
ROU 099c 4 57–65 e3/e4
ALZ 342 5 60–77 e3/e4
ALZ 338 4 59–66 e3/e4
ALZ 005 5 60–72 e3/e4
NOTE.—All APP, PSEN1, and PSEN2 were wild
type.
a Three generations were studied per family.
b Of the index case.
c Family included in the population study.
large pedigree (Campion et al. 1995a). Two patients with
familial cases had ADAD. Finally, 17 patients had a fa-
milial history of AD that did not correspond with either
ADEOAD or ADAD. Global prevalences (per 100,000
inhabitants at risk) for EOAD and ADEOAD were es-
timated as 41.2 and 5.3, respectively. Sex-specific prev-
alences for EOAD and ADEOAD are shown in table 1.
Mutational analysis of PSEN1, APP, and PSEN2 was
then performed in 34 French families with ADEOAD.
Characteristics of the pedigrees with ADEOAD and de-
tails of the mutations detected are shown in tables 2 and
3. Sixteen different PSEN1 mutations (not including the
polymorphism Glu318Gly) and two different APP mu-
tations were found in a total of 20 and 5 families, re-
spectively. Four PSEN1 mutations (Thr147Ile,
Trp165Cys, Leu173Trp, and Ser390Ile) had not been
reported elsewhere. The mutation Leu173Trp is, to our
knowledge, the PSEN1 mutation associated with the
youngest AAO (24 years) so far reported for an
ADEOAD case. Neuropathological confirmation of the
diagnosis was obtained for one patient from this kin-
dred. The common Pro264Leu PSEN1 mutation was
associated, in family SAL 1633, with a particular phe-
notype including spastic paresis, which had so far been
associated only with a deletion of exon 9 (Crook et al.
1998) and a missense mutation at codon 278 (Kwok et
al. 1997). Finally, a novel APP mutation, which intro-
duces a Val to Met substitution near the g-secretase
cleavage site, was detected at codon 715 (Ancolio et al.
1999). In 13 families (see tables 2 and 3) DNA from
relatives was available, allowing us to test the cosegre-
gation of the mutation found in the index patient with
the disease. All affected subjects for which DNA was
available were mutation carriers. No asymptomatic sub-
ject 60 years of age was a mutation carrier. If we as-
sume that the PSEN1 Glu318Gly substitution found in
pedigree ALZ 059 (table 2) is a noncausative polymor-
phism (Mattila et al. 1998; Dermaut et al. 1999), no
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Table 5
Estimation of Prevalence (per 100,000 Inhabitants) of EOAD in
Three Other Studies
STUDY
NO. OF
PREVALENCE
Individuals
at Risk
(range [years]) Cases
Schoenberg et al. (1985) 4,422 (40–59) 2a 45.2
Kokmen et al. (1989)b 7,422 (45–59) 2 26.9
Sulkava et al. (1985) 5,466 (30–59) 1c 18.2
a “Severe dementia” of uncertain etiology.
b Register of cases.
c “Primary degenerative dementia” expected to correspond to AD
in 180% of cases.
PSEN1, PSEN2, or APP pathological mutation was de-
tected in a total of 10 pedigrees with ADEOAD (tables
2 and 3). In these 10 families, we sequenced not only
exons 16 and 17 of APP but also exons 7, 8, and 18,
since they correspond to important functional
regions—the Kunitz inhibitor domain and the reinter-
nalization domain, respectively—and this screening re-
mained negative. Nine families with ADAD were also
screened for APP and presenilin mutations. As indicated
in table 4, we identified no mutation in these families.
APOE genotyping revealed that, among the 17 pa-
tients with non-ADEOAD or ADAD familial cases iden-
tified during the prevalence study, 5 (29%) were ho-
mozygous, and 10 (59%) were heterozygous, for the e4
allele. In contrast, no index patient with ADEOAD or
ADAD who was included in the mutational study carried
the APOE e4/e4 genotype (tables 2–4). The frequency
of the APOE e4 allele among these index patients was
.15 and thus did not differ from that observed in the
general French population.
Discussion
To assess the prevalence of ADEOAD, we conducted
a population-based study of presenile AD cases. The
strength of our study lies in (1) the neurological ex-
amination of index cases allowing accurate diagnoses,
(2) the use of a structured family-history questionnaire
with multiple informants for checking of information
about relatives, (3) the outlining of stringent criteria for
ADEOAD or ADAD, and (4) the length of our follow-
up period. Since ascertainment was done on the basis of
detection, by physicians, of eligible cases, it could be
argued that some patients may have been missed because
they did not come to medical attention. This hypothesis
is very unlikely, however, because EOAD is a debilitating
illness that affects subjects who are still active and has
a large impact on everyday life. In France, to obtain
appropriate social assistance, affected individuals must
visit a physician. Most of the epidemiological studies on
AD have measured prevalence of the disease in elderly
populations and have thus ascertained patients with AD
with AAO 160—or even 165 years. Only three other
studies have estimated the prevalence of EOAD (table
5). The prevalence of EOAD reported in this study is at
the upper boundary of those in other reports.
Although our patients were referred irrespective of
their family history, we found that a large proportion
(24 [62%] of 39) of patients with EOAD indeed had a
positive family history. This proportion is similar to that
reported by Van Duijn et al. (1994) in another popu-
lation-based study, in which patients with EOAD (with
AAO !65 years) from four regions of the Netherlands
were ascertained. In that study, 61% of index patients
had at least one affected first-degree relative.
In the present study, only five patients (belonging to
three families) fulfilled the rigid criteria for ADEOAD.
This low proportion (13%) of ADEOAD cases among
EOAD cases is comparable to—albeit slightly less
than—that estimated in our previous study, which relied
on patients with EOAD ascertained through consecutive
admission to several French hospitals (Campion et al.
1995a and 1995b).
Sequencing analysis revealed that ADEOAD in 24
(71%) of 34 French families studied was attributable to
PSEN1 or APP mutations. Evidence for cosegregation
with the disease was not available in all families (tables
2 and 3), but the pathological nature of most PSEN1
mutations has now been established. Nevertheless, we
cannot exclude the fact that some mutations are non-
pathogenic. The high proportion of PSEN1 and APP
mutations described in the present study sharply con-
trasts with that reported by Cruts et al. (1998). The low
percentage (18%) of families with ADEOAD with
PSEN1 or APP mutations reported by those authors
might be explained by their inclusion criteria (i.e., at
least three patients with dementia in two generations),
which could not differentiate between families with
ADEOAD and other types of familial aggregation. Prob-
ably some multiplex families with EOAD have been mis-
classified by Cruts et al. as autosomal dominant. This
latter hypothesis is supported by the high prevalence
(31%) of APOE e4/e4 genotypes among their “auto-
somal dominant” probands, whereas in the present sam-
ple no index patient with ADEOAD included in the mu-
tational analysis had the APOE e4/e4 genotype (see
tables 2 and 3). It is now well established that the e4
allele is a potent risk factor for EOAD (Van Duijn et al.
1994; Perez-Tur et al. 1995a) and that the presence of
one e4 allele in an affected proband sharply increases
the cumulative incidence of AD in first-degree relatives.
This increased risk is obvious when the proband is ho-
mozygous for the e4 allele (Farrer et al. 1995; Martinez
et al. 1998), and these data are confirmed by the pro-
portion (29%) of APOE e4/e4 genotypes, among our
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familial cases, that did not correspond to either
ADEOAD or ADAD cases.
The absence of APP, PSEN1, or PSEN2 mutation in
10 families with ADEOAD might be explained either by
a mutation located outside the regions that we analyzed
or by the involvement of another gene. Interestingly, in
the nine families with ADAD, no APP or PSEN1 mu-
tation was detected (table 4).
We conclude that (1) PSEN1 and APP mutations are
involved in the majority of ADEOAD cases and (2) that
nonpenetrance of PSEN1 and APP mutations by age 60
years is infrequent. These findings are important for ge-
netic counseling and for the strategy of molecular
analyses.
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